Bacterial meningitis: Current therapy and possible future treatment options

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 11, 2011, Pages 1053-1065

  Woehrl, Bianca ^a   Klein, Matthias ^a   Grandgirard, Denis ^b   Koedel, Uwe ^a   Leib, Stephen ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

complement; daptomycin; dexamethasone; matrix metalloproteinases; rifampicin; roscovitine; Streptococcus pneumoniae

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CASPASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CORTICOSTEROID; DAPTOMYCIN; DEXAMETHASONE; DOXYCYCLINE; ECULIZUMAB; GLYCEROL; MATRIX METALLOPROTEINASE; MEROPENEM; PENICILLIN G; PEXELIZUMAB; PLACEBO; RIFAMPICIN; ROSCOVITINE; VANCOMYCIN;

ADJUVANT THERAPY; ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; BRAIN INJURY; COMBINATION CHEMOTHERAPY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; ENZYME INHIBITION; HAEMOPHILUS MENINGITIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; LEUKOCYTE ACTIVATION; LISTERIOSIS; MENINGOCOCCEMIA; MENINGOCOCCOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOLECULAR PATHOLOGY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PNEUMOCOCCAL MENINGITIS; REVIEW; SEIZURE; SUBARACHNOID SPACE; THERAPY DELAY; TISSUE INJURY; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CHILD, PRESCHOOL; DISEASE MANAGEMENT; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; INFANT, NEWBORN; MENINGITIS, BACTERIAL; MICE; MIDDLE AGED; NEISSERIA MENINGITIDIS; NEUTROPHILS; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; SUBARACHNOID SPACE; TIME FACTORS;

EID: 80155142492     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.129     Document Type: Review

References (133)

1. De Gans J, Van de Beek D. Dexamethasone in adults with bacterial meningitis. N. Engl. J. Med. 347, 1549-1556 (2002).
2. Auburtin M, Wolff M, Charpentier J et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit. Care Med. 34, 2758-2765 (2006).
3. Heckenberg SG, de Gans J, Brouwer MC et al. Clinical features, outcome, and meningococcal genotype in 258 adults with meningococcal meningitis: a prospective cohort study. Medicine 87, 185-192 (2008).
4. Schmidt H, Heimann B, Djukic et al. Neuropsychological sequelae of bacterial and viral meningitis. Brain 129, 333-345 (2006).
5. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moisi JC, Were F, Levine OS. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Med. 7, 47 (2009).
6. Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J. Infect. 61, 114-124 (2010).
7. Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain 126, 1015-1025 (2003).
8. Van de Beek D, De Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N. Engl. J. Med. 351, 1849-1859 (2004).
9. Katchanov J, Siebert E, Endres M, Klingebiel R. Focal parenchymal lesions in community-acquired bacterial meningitis in adults: a clinico-radiological study. Neuroradiology 51, 723-729 (2009).
10. Koedel U, Klein M, Pfister HW. New understandings on the pathophysiology of bacterial meningitis. Curr. Opin. Infect. Dis. 23, 217-223 (2010).
11. Chaudhuri A, Martin PM, Kennedy PG et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Eur. J. Neurol. 15, 649-659 (2008).
12. Proulx N, Frechette D, Toye B, Chan J, Kravcik S. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 98, 291-298 (2005).
13. Koster-Rasmussen R, Korshin A, Meyer CN. Antibiotic treatment delay and outcome in acute bacterial meningitis. J. Infect. 57, 449-454 (2008).
14. Klein M, Pfister, HW, Leib SL, Koedel U. Therapy of community-acquired acute bacterial meningitis: the clock is running. Expert Opin. Pharmacother. 10, 2609-2623 (2009).
15. Cartwright K, Reilly S, White D, Stuart J. Early treatment with parenteral penicillin in meningococcal disease. BMJ 305, 143-147 (1992).
16. Harnden A, Ninis N, Thompson M et al. Parenteral penicillin for children with meningococcal disease before hospital admission: case-control study. BMJ 332, 1295-1298 (2006).
17. Sudarsanam T, Rupali P, Tharyan P, Abraham OC, Thomas K. Pre-admission antibiotics for suspected cases of meningococcal disease. Cochrane Database Syst. Rev. 1, CD005437 (2008).
18. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39, 1267-1284 (2004).
19. Reinert R, Reinert S, van der Linden M, Cil MY, Al-Lahham A, Appelbaum P. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob. Agents Chemother. 49, 2903-2013 (2005).
20. WHO. Standardized treatment of bacterial meningitis in Adrica in epidemic and non-epidemic situations. World Health Organization, Geneva, Switzerland (2007).
21. Prasad K, Kumar A, Gupta PK, Singhal T. Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis. Cochrane Database Syst. Rev. 17, CD001832 (2007).
22. Singhi P, Kaushal M, Singhi S, Ray P. Seven days vs. 10 days ceftriaxone therapy in bacterial meningitis. J. Trop. Pediatr. 48, 273-279 (2002).
23. Lin TY, Chrane DF, Nelson JD, McCracken GH Jr. Seven days of ceftriaxone therapy is as effective as ten days' treatment for bacterial meningitis. JAMA 253, 3559-3563 (1985).
24. Molyneux E, Nizami SQ, Saha S et al.; CSF 5 Study Group. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet 377, 1837-1845 (2011).
25. Pfister HW, Eiffert H, Nau R, Schmutzhard E, Tauber MG. Bacterial (purulent) meningoencephalitis. In: Guidelines on Neurologic Diagnosis and Therapy of the German Neurological Society (DGN) (4th Edition). Diener H-C, Putzki N (Eds). Georg Thieme Verlag, Stuttgart, Germany (2008).
26. Assiri AM, Alasmari FA, Zimmerman VA, Baddour LM, Erwin PJ, Tleyjeh IM. Corticosteroid administration and outcome of adolescents and adults with acute bacterial meningitis: a meta-analysis. Mayo Clin. Proc. 84, 403-409 (2009).
27. Peltola H, Roine I. Improving the outcomes in children with bacterial meningitis. Curr. Opin. Infect. Dis. 22, 250-255 (2009).
28. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids in acute bacterial meningitis. Cochrane Database Syst. Rev. (3), CD004405 (2003).
29. van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect. Dis. 4, 139-143 (2004).
30. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev. 24, CD004405 (2007).
31. Brouwer MC, McIntyre P, de Gans J, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev. 8, CD004405 (2010).
32. Weisfelt M, Hoogman M, van de BD, de Gans J, Dreschler WA, Schmand BA. Dexamethasone and lonγ-term outcome in adults with bacterial meningitis. Ann. Neurol. 60, 456-468 (2006).
33. Lin AL, Safdieh JE. The evaluation and management of bacterial meningitis: current practice and emerging developments. Neurologist 16, 143-151 (2010).
34. Molyneux EM, Walsh AL, Forsyth H et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet 360, 211-218 (2002).
35. Nguyen TH, Tran TH, Thwaites G et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N. Engl. J. Med. 357, 2431-2440 (2007).
36. Scarborough M, Gordon SB, Whitty CJ et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N. Engl. J. Med. 357, 2441-2450 (2007).
37. Peterković V, Trkulja V, Kutleša M, Krajinović V, Lepur D. Dexamethasone for adult community acquired-bacterial meningitis: 20 years of experience in daily practice. J. Neurol. DOI: 10.1007/ s00415-011-6150-6 (2011) (Epub ahead of print).
38. Schut ES, Brouwer MC, de Gans J, Florquin S, Troost D, van de Beek D. Delayed cerebral thrombosis after initial good recovery from pneumococcal meningitis. Neurology 73(23), 1988-1995 (2009).
39. Blaser C, Klein M, Grandgirard D et al. Adjuvant glycerol is not beneficial in experimental pneumococcal meningitis. BMC Infect. Dis. 10, 84 (2010).
40. Peltola H, Roine I, Fernandez J et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 45, 1277-1286 (2007).
41. Ajdukiewicz KM, Cartwright K, Scarborough M et al. A double blind, randomised controlled trial of glycerol adjuvant therapy in adult bacterial meningitis in a high HIV seroprevalence setting in Malawi. Lancet Infect. Dis. 11, 293-300 (2011).
42. Donnelly S, Loscher C, Mills KH, Lynch MA. Glycerol-induced seizure: involvement of IL-1β and glutamate. Neuroreport 10, 1821-1825 (1999).
43. Brouwer MC, van de Beek D. Glycerol in bacterial meningitis: one strike and out? Lancet Infect. Dis. 11, 257-258 (2011).
44. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat. Immunol. 7, 354-359 (2006).
45. Johnston M, Zakharov A, Papaiconomou C, Salmasi G, Armstrong D. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res. 1, 2 (2004).
46. Pachter JS, De Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J. Neuropathol. Exp. Neurol. 62, 593-604 (2003).
47. Dujardin BC, Driedijk PC, Roijers AF, Out TA. The determination of the complement components C1q, C4 and C3 in serum and cerebrospinal fluid by radioimmunoassay. J. Immunol. Methods 80, 227-237 (1985).
48. Stahel PF, Nadal D, Pfister HW, Paradisis PM, Barnum SR. Complement C3 and factor B cerebrospinal fluid concentrations in bacterial and aseptic meningitis. Lancet 349, 1886-1887 (1997).
49. Pashenkov M, Link H. Dendritic cells and immune responses in the central nervous system. Trends Immunol. 23, 69-70 (2002).
50. Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J. Leukoc. Biol. 75, 388-397 (2004).
51. Mukhopadhyay S, Gordon S. The role of scavenger receptors in pathogen recognition and innate immunity. Immunobiology 209, 39-49 (2004).
52. McGreal EP, Miller JL, Gordon S. Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr. Opin. Immunol. 17, 18-24 (2005).
53. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 61, 1013-1021 (2002).
54. Letiembre M, Hao W, Liu Y et al. Innate immune receptor expression in normal brain aging. Neuroscience 146(1), 248-254 (2007).
55. Small PM, Tauber MG, Hackbarth CJ, Sande MA. Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits. Infect. Immun. 52, 484-487 (1986).
56. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat. Rev. Microbiol. 6, 288-301 (2008).
57. Fischer H, Tomasz A. Production and release of peptidoglycan and wall teichoic acid polymers in pneumococci treated with β-lactam antibiotics. J. Bacteriol. 157, 507-513 (1984).
58. Moscoso M, Claverys JP. Release of DNA into the medium by competent Streptococcus pneumoniae: kinetics, mechanism and stability of the liberated DNA. Mol. Microbiol. 54, 783-794 (2004).
59. Stucki A, Cottagnoud M, Winkelmann V, Schaffner T, Cottagnoud P. Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H] choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall. Antimicrob. Agents Chemother. 51, 2249-2252 (2007).
60. Grandgirard D, Oberson K, Bühlmann A, Gäumann R, Leib SL. Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 54, 1323-1326 (2010).
61. Tuomanen E, Tomasz A, Hengstler B, Zak O. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J. Infect. Dis. 151, 535-540 (1985).
62. Tuomanen E, Hengstler B, Zak O, Tomasz A. Induction of meningeal inflammation by diverse bacterial cell walls. Eur. J. Clin. Microbiol. 5, 682-684 (1986).
63. Tuomanen EI, Saukkonen K, Sande S, Cioffe C, Wright SD. Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes. J. Exp. Med. 170, 959-969 (1989).
64. Malley R, Henneke P, Morse SC et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl Acad. Sci. USA 100, 1966-1971 (2003).
65. Koedel U, Angele B, Rupprecht T et al. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J. Immunol. 170, 438-444 (2003).
66. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163, 1-5 (1999).
67. Schroeder NW, Morath S, Alexander C et al. Lipoteichoic acid (LTA) of S. pneumoniae and S. aureus activates immune cells via toll-like receptor (TLR)-2, LPS binding protein (LBP) and CD14 while TLR-4 and MD-2 are not involved. J. Biol. Chem. 278, 15587-15594 (2003).
68. Han SH, Kim JH, Martin M, Michalek SM, Nahm MH. Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect. Immun. 71, 5541-5548 (2003).
69. Mogensen TH, Paludan SR, Kilian M, Ostergaard L. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J. Leukoc. Biol. 80, 267-277 (2006).
70. Klein M, Angele B, Pfister HW, Wagner H, Koedel U, Kirschning CJ. Detection of pneumococcal infection of the central nervous system depends upon TLR2 and TLR4. J. Infect. Dis. 198, 1028-1036 (2008).
71. Koedel U, Rupprecht T, Angele B et al. MyD88 is required for mounting a robust host immune response to Streptococcus pneumoniae in the CNS. Brain 127, 1437-1445 (2004).
72. Koedel U, Winkler F, Angele B, Fontana A, Flavell RA, Pfister HW. Role of caspase-1 in experimental pneumococcal meningitis: evidence from pharmacologic caspase inhibition and caspase-1-deficient mice. Ann. Neurol. 51, 319-329 (2002).
73. Zwijnenburg PJ, Van der Poll T, Florquin S, Roord JJ, Van Furth AM. IL-1 receptor type 1 gene-deficient mice demonstrate an impaired host defense against pneumococcal meningitis. J. Immunol. 170, 4724-4730 (2003).
74. Zwijnenburg PJ, Van der Poll T, Florquin S et al. Interleukin-18 gene-deficient mice show enhanced defense and reduced inflammation during pneumococcal meningitis. J. Neuroimmunol. 138, 31-37 (2003).
75. Liu X, Chauhan VS, Young AB et al. NOD2 mediates inflammatory responses of primary murine glia to Streptococcus pneumoniae. Glia 58, 839-847 (2010).
76. Opitz B, Puschel A, Schmeck B et al. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J. Biol. Chem. 279, 36426-36432 (2004).
77. Witzenrath M, Pache F, Lorenz D et al. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J. Immunol. 187, 434-440 (2011).
78. Bogaert D, Thompson CM, Trzcinski K, Malley R, Lipsitch M. The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model. Vaccine 28, 681-685 (2010).
79. Rupprecht TA, Angele B, Klein M et al. Complement C1q and C3 are critical for the innate immune response to Streptococcus pneumoniae in the central nervous system. J. Immunol. 178, 1861-1869 (2007).
80. Koedel U, Klein M, Pfister HW. Modulation of brain injury as a target for adjunctive therapy in bacterial meningitis. Curr. Infect. Dis. Rep. 12, 266-273 (2010).
81. Johnson AJ, Ayvazian JH, Tillett WS. Crystalline pancreatic desoxyribonuclease as an adjunct to the treatment of pneumococcal menignitis. N. Engl. J. Med. 260, 893-900 (1959).
82. Klein M, Koedel U, Pfister HW. Oxidative stress in pneumococcal meningitis: a future target for adjunctive therapy? Prog. Neurobiol. 80, 269-280 (2006).
83. Meli DN, Christen S, Leib SL. Matrix-metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J. Infect. Dis. 187, 1411-1415 (2003).
84. Kastenbauer S, Koedel U, Becker BF, Pfister HW. Oxidative stress in bacterial meningitis in humans. Neurology 58, 186-191 (2002).
85. de Menezes CC, Dorneles AG, Sperotto RL, Duarte MM, Schetinger MR, Loro VL. Oxidative stress in cerebrospinal fluid of patients with aseptic and bacterial meningitis. Neurochem. Res. 34, 1255-1260 (2009).
86. Hamed SA, Hamed EA, Zakary MM. Oxidative stress and S-100B protein in children with bacterial meningitis. BMC Neurol. 9, 51 (2009).
87. Gerber J, Nau R. Mechanisms of injury in bacterial meningitis. Curr. Opin. Neurol. 23, 312-318 (2010).
88. Kieseier BC, Paul R, Koedel U et al. Differential expression of matrix metalloproteinases in bacterial meningitis. Brain 122, 1579-1587 (1999).
89. Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, Hollander GA. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin. Infect. Dis. 31, 80-84 (2000).
90. Leib SL, Leppert D, Clements J, Täuber MG. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect. Immun. 68, 615-620 (2000).
91. Meli DN, Loeffler JM, Baumann P et al. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-α converting enzyme attenuates seizures and injury of the cerebral cortex. J. Neuroimmunol. 151, 6-11 (2004).
92. Hu J, Van den Steen PE, Sang QX et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6, 480-498 (2007).
93. Hirst RA, Kadioglu A, O'Callaghan C, Andrew PW. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin. Exp. Immunol. 138, 195-201 (2004).
94. Weber JR, Tuomanen EI. Cellular damage in bacterial meningitis: an interplay of bacterial and host driven toxicity. J. Neuroimmunol. 184, 45-52 (2007).
95. Braun JS, Sublett JE, Freyer D et al. Pneumococcal pneumolysin and H2O2 mediate brain cell apoptosis during meningitis. J. Clin. Invest. 109, 19-27 (2002).
96. Zysk G, Schneider-Wald BK, Hwang JH et al. Pneumolysin is the main inducer of cytotoxicity to brain microvascular endothelial cells caused by Streptococcus pneumoniae. Infect. Immun. 69, 845-852 (2001).
97. Hirst RA, Gosai B, Rutman A, Andrew PW, O'Callaghan C. Streptococcus pneumoniae damages the ciliated ependyma of the brain during meningitis. Infect. Immun. 71, 6095-6100 (2003).
98. Hirst RA, Gosai B, Rutman A, Guerin CJ, Nicotera P, Andrew PW, O'Callaghan C. Streptococcus pneumoniae deficient in pneumolysin or autolysin has reduced virulence in meningitis. J. Infect. Dis. 197, 744-751 (2008).
99. Vesely JJ, Pien FD, Pien BC. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 18, 345-357 (1998).
100. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology 81, 79-91 (2008).
101. Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr. Opin. Chem. Biol. 13, 144-151 (2009).
102. Paris MM, Hickey SM, Uscher MI, Shelton S, Olsen KD, McCracken GH Jr. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 38, 1320-1324 (1994).
103. Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meningesxJ. Antimicrob. Chemother. 29, 719-724 (1992).
104. Cottagnoud P, Pfister M, Acosta F et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. 48, 3928-3933 (2004).
105. Spanjaard L, Vandenbroucke-Grauls CM. Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid. Antimicrob. Agents Chemother. 52, 1850-1851 (2008).
106. Le J, Bookstaver PB, Rudisill CN et al. Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy. Ann. Pharmacother. 44, 2001- 2006 (2010).
107. Riser MS, Bland CM, Rudisill CN, Bookstaver PB. Cerebrospinal fluid penetration of high-dose daptomycin in suspected Stapholycoccus aureus meningitis. Ann. Pharmacother. 44, 1832-1835 (2010).
108. Kullar R, Chin JN, Edwards DJ, Parker D, Coplin WM, Rybak MJ. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob. Agents Chemother. 55, 3505-3509 (2011).
109. Grandgirard D, Schurch C, Cottagnoud P, Leib SL. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 51, 2173-2178 (2007).
110. Bottcher T, Gerber J, Wellmer A et al. Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J. Infect. Dis. 181, 2095-2098 (2000).
111. Nau R, Wellmer A, Soto A et al. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J. Infect. Dis. 179, 1557-1560 (1999).
112. Spreer A, Lugert R, Stoltefaut V, Hoecht A, Eiffert H, Nau R. Short-term rifampicin pretreatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis. Crit. Care Med. 37, 2253-2258 (2009).
113. Grandgirard D, Burri M, Oberson K, Bühlmann A, Simon F, Leib SL. In infant rat pneumococcal meningitis, ceftriaxone plus daptomycin versus cefrtriaxone attenuates brain damage and hearing loss while ceftriaxone plus rifampicin does not. Presented at: ECCMID 2009. Helsiniki, Finland, 16-19 May 2009 (Abstract O381).
114. Hoffmann O, Priller J, Prozorovski T et al. TRAIL limits excessive host immune responses in bacterial meningitis. J. Clin. Invest. 117, 2004-2013 (2007).
115. Rossi AG, Sawatzky DA, Walker A et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 12, 1056-1064 (2006).
116. Koedel U, Frankenberg T, Kirschnek S et al. Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis. PLoS Pathog. 5, e1000461 (2009).
117. Meli DN, Coimbra RS, Erhart DG et al. Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect. Immun. 74(7), 3890-3896 (2006).
118. Lepper MH, Dowling HF. Treatment of pneumococcal meningitis with penicillin compared with penicillin plus aureomycin. Arch. Intern. Med. 88, 489-494 (1951).
119. Leib SL, Clements JM, Lindberg RL et al. Inhibition of matrix metalloproteinases and tumour necrosis factor a converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 124, 1734-1742 (2001).
120. Paul R, Obermaier B, Van ZJ et al. Myeloid Src kinases regulate phagocytosis and oxidative burst in pneumococcal meningitis by activating NADPH oxidase. J. Leukoc. Biol. 84, 1141-1150 (2008).
121. Woehrl B, Haubner C, Angele B, Pfister HW, Koedel U. Role of the anaphylatoxin C5a in the pathogenesis of pneumococcal meningitis. Presented at: ICAAC 2010. Boston, MA, USA, 12-14 September 2010 (Abstract β-075).
122. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797 (2010).
123. Kadurugamuwa JL, Hengstler B, Bray MA, Zak O. Inhibition of complement-factor- 5a-induced inflammatory reactions by prostaglandin E2 in experimental meningitis. J. Infect. Dis. 160, 715-719 (1989).
124. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 281(5381), 1312-1316. (1998).
125. Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, Tuomanen EI. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat. Med. 5, 298-302 (1999).
126. Gianinazzi C, Grandgirard D, Imboden H et al. Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis. Acta Neuropathol. 105, 499-507 (2003).
127. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 24, 677-736 (2001).
128. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10, 381-391 (2000).
129. Bifrare YD, Kummer J, Joss P, Täuber MG, Leib SL. Brain-derived neurotrophic factor protects against multiple forms of brain injury in bacterial meningitis. J. Infect. Dis. 191, 40-45 (2005).
130. Li L, Shui QX, Zhao ZY. Regulation of brain-derived neurotrophic factor (BDNF) expression following antibiotic treatment of experimental bacterial meningitis. J. Child. Neurol. 18, 828-834 (2003).
131. Li L, Shui QX, Li X. Neuroprotective effects of brain-derived neurotrophic factor (BDNF) on hearing in experimental pneumococcal meningitis. J. Child. Neurol. 20, 51-56 (2005).
132. Tyler KL. Bacterial meningitis: an urgent need for further progress to reduce mortality and morbidity. Neurology 70, 2095-2096 (2008).
133. Auer M, Pfister LA, Leppert D, Tauber MG, Leib SL. Effects of clinically used antioxidants in experimental pneumococcal meningitis. J. Infect. Dis. 182, 347-350 (2000).